Alphabet Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Alphabet Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $402.84B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $350.02B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $307.39B | Feb 5, 2026 |
| FY2021 | Dec 31, 2021 | $257.64B | Feb 2, 2022 |
| FY2021 | Dec 31, 2020 | $182.53B | Feb 2, 2022 |
| FY2021 | Dec 31, 2019 | $161.86B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $136.82B | Feb 3, 2021 |
| FY2017 | Dec 31, 2017 | $110.86B | Feb 6, 2018 |
| FY2017 | Dec 31, 2016 | $90.27B | Feb 6, 2018 |
| FY2017 | Dec 31, 2015 | $74.99B | Feb 6, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $350.02B | Feb 5, 2025 |
| FY2024 | Dec 31, 2023 | $307.39B | Feb 5, 2025 |
| FY2024 | Dec 31, 2022 | $282.84B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $257.64B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $182.53B | Feb 3, 2023 |
| FY2019 | Dec 31, 2019 | $161.86B | Feb 4, 2020 |
| FY2019 | Dec 31, 2018 | $136.82B | Feb 4, 2020 |
| FY2019 | Dec 31, 2017 | $110.86B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $90.27B | Feb 5, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.17B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $100.12B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $73.80B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $59.97B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $76.03B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $40.27B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $34.34B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $30.74B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $12.66B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $19.48B | Feb 5, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.04B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $112.39B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $84.29B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $74.84B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $78.71B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $41.22B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $34.23B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $27.52B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $26.18B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $23.72B | Feb 5, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.09B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $49.33B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $45.43B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $39.50B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $31.56B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $27.57B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $26.02B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $21.42B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $16.63B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $13.95B | Feb 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.71B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $125.30B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $101.75B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $91.50B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $91.65B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $65.12B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $54.52B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $47.97B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $37.09B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $36.04B | Feb 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.45B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $52.54B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $32.25B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $31.49B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $24.64B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $22.28B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $23.55B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $25.14B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $13.18B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $10.21B | Feb 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $595.28B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $450.26B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $402.39B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $365.26B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $359.27B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $319.62B | Feb 2, 2022 |
| FY2020 | Dec 31, 2019 | $275.91B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $232.79B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $197.30B | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $167.50B | Feb 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.02B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $125.17B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $119.01B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $109.12B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $107.63B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $97.07B | Feb 2, 2022 |
| FY2020 | Dec 31, 2019 | $74.47B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $55.16B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $44.79B | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $28.46B | Feb 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $415.27B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $325.08B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $283.38B | Feb 5, 2026 |
| FY2025 | Dec 31, 2022 | $256.14B | Feb 5, 2026 |
| FY2024 | Dec 31, 2021 | $251.64B | Feb 5, 2025 |
| FY2023 | Dec 31, 2020 | $222.54B | Jan 31, 2024 |
| FY2022 | Dec 31, 2019 | $201.44B | Feb 3, 2023 |
| FY2021 | Dec 31, 2018 | $177.63B | Feb 2, 2022 |
| FY2020 | Dec 31, 2017 | $152.50B | Feb 3, 2021 |
| FY2019 | Dec 31, 2016 | $139.04B | Feb 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.38B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $31.89B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $29.20B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $28.96B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $22.96B | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | $21.18B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $20.62B | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | $17.89B | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | $16.75B | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | $16.47B | Feb 5, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $324.06B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $245.08B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $211.25B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $195.56B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $191.48B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $163.40B | Feb 2, 2022 |
| FY2020 | Dec 31, 2019 | $152.12B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $134.89B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $113.25B | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $105.13B | Feb 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.71B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $23.47B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $24.05B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $21.88B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | $20.95B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $26.47B | Feb 2, 2022 |
| FY2020 | Dec 31, 2019 | $18.50B | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | $16.70B | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | $10.72B | Feb 5, 2019 |
| FY2018 | Dec 31, 2016 | $12.92B | Feb 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.09B | Feb 5, 2026 |
| FY2024 | Dec 31, 2024 | $12.00B | Feb 5, 2025 |
| FY2024 | Dec 31, 2023 | $13.00B | Feb 5, 2025 |
| FY2022 | Dec 31, 2022 | $15.31B | Feb 3, 2023 |
| FY2021 | Dec 31, 2021 | $15.44B | Feb 2, 2022 |
| FY2020 | Dec 31, 2020 | $15.32B | Feb 3, 2021 |
| FY2019 | Dec 31, 2019 | $4.69B | Feb 4, 2020 |
| FY2018 | Dec 31, 2018 | $4.06B | Feb 5, 2019 |
| FY2017 | Dec 31, 2017 | $4.03B | Feb 6, 2018 |
| FY2016 | Dec 31, 2016 | $4.00B | Feb 3, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | 49 | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | 44 | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | 18 | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | 28 | Feb 5, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Jan 31, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | 49 | Feb 2, 2022 |
| FY2020 | Dec 31, 2018 | 43 | Feb 3, 2021 |
| FY2019 | Dec 31, 2017 | 18 | Feb 4, 2020 |
| FY2018 | Dec 31, 2016 | 27 | Feb 5, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.09B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 12.21B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 12.46B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | 12.85B | Jan 31, 2024 |
| FY2022 | Dec 31, 2021 | 13.24B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | 675.22M | Feb 2, 2022 |
| FY2020 | Dec 31, 2019 | 688.34M | Feb 3, 2021 |
| FY2019 | Dec 31, 2018 | 695.56M | Feb 4, 2020 |
| FY2018 | Dec 31, 2017 | 694.78M | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | 691.29M | Feb 6, 2018 |